Pharmaceuticals

Porton

Porton released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 886.04 M, actual EPS CNY 0.05

Porton FY2026 Q1 Earnings Release Scheduled for April 23 After-Market BJT

Porton released FY2025 annual earnings on April 3 After-Market (BJT), actual revenue CNY 3.42 B (forecast CNY 3.535 B), actual EPS CNY 0.18 (forecast CNY 0.23)

Porton released FY2025 Q4 earnings on April 3 After-Market (BJT), actual revenue CNY 875.4 M, actual EPS CNY 0.0302

Porton to Release FY2025 Earnings on April 4 After-Market (BJT), Forecast Revenue CNY 3.535 B, EPS CNY 0.23

Porton released FY2025 Q3 earnings on October 24 During-Market (BJT), actual revenue CNY 923.49 M, actual EPS CNY 0.1024

Porton released FY2025 9 Months earnings on October 24 During-Market (BJT), actual revenue CNY 2.544 B, actual EPS CNY 0.1403

Porton to Release FY2025 Q3 Earnings Report on October 25 During-Market BJT

Porton released FY2025 Semi-Annual Earnings on August 22 After-Market (BJT), actual revenue CNY 1.621 B, actual EPS CNY 0.05

Porton released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue CNY 819.78M, actual EPS CNY 0.0479

Porton to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Bontea Corporation's Q2 Earnings Preview: Expected to Return to Profit

Botten Shares 2025 First Half Year Net Profit Expected to Turn from Loss to Profit

Bontea Smart Through EU QP Audit

Botenn Responds to Investor Proposal for Share Repurchase

Suzhou Bottan and Henan Hualong Reach MATC Cell Therapy Collaboration

Bioton Shares Outlook for Profitability in 2025

Bontan accepts institutional research

Bontao Shares Q1 2025 Net Loss of 428.42 Ten Thousand Yuan

Porton released FY2025 Q1 earnings on April 24 Pre-Market BJT, actual revenue CNY 801.16 M, actual EPS CNY -0.01

300363

Porton released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 2.544 billion yuan, a year-on-year increase of 19.72%. The net profit attributable to shareholders of the listed company was 79.9154 million yuan, a year-on-year increase of 138.71%. The net profit after deducting non-recurring gains and losses was 53.6788 million yuan, a year-on-year increase of 125.14%. The basic earnings per share were 0.15 yuan

Zhitong

Porton released its performance for the first three quarters, with a net profit attributable to the parent company of 79.9154 million yuan, an increase of 138.71%

According to the Zhitong Finance APP, Porton disclosed its performance forecast for the first three quarters of 2025. The company expects a net profit attributable to shareholders of the listed company to be between 73.2 million yuan and 88.2 million yuan, turning a profit; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be between 50 million yuan and 65 million yuan

Porton issued a profit warning, expecting a net profit attributable to shareholders of 73.2 million to 88.2 million yuan in the first three quarters, turning losses into profits

603127

06127

002262

000813

603590

688091

Innovative drug concept stocks fluctuated and rose sharply, DEZHAN HEALTHCARE hit the limit up, Porton, JOINN, NHWA, Konruns, and SHANGHAI YIZHONG followed suit

JOINN

NHWA

DEZHAN HEALTHCARE

Konruns

SHANGHAI YIZHONG

Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

300347

03347

300725

688202

Zhejiang Merchants Securities released a research report indicating that from Q1 2024 to Q2 2025, the revenue of leading CXO companies will increase quarter-on-quarter and year-on-year. It is expected that the year-on-year revenue growth will return to positive in Q1 2025, reaching 8.2%, and further increase to 11.6% in Q2 2025. The high level of ongoing construction projects shows that CXO companies are optimistic about capacity expansion. Overall, the performance and fundamental turning point of the CXO industry are the main driving factors

Tigermed

TIGERMED

PHARMABLOCK

Medicilon

Zhejiang Merchants Securities: The growth trend of the CXO sector in 25H1 continues to improve, and the construction projects remain at a high level

According to Porton, on September 2nd, Suzhou Porton Biopharma Co., Ltd. and Zhejiang Tianyu Life Science Technology Co., Ltd. announced a strategic cooperation to jointly promote the research and industrialization of NK cell therapy technology. According to the agreement, Porton Biopharma will provide process development, GMP production, and registration application services for Tianyu Life's NK cell therapy project, assisting Tianyu Life in successfully obtaining clinical approval for its NK cell therapy drugs

Porton Biotech and Tianyu Life have reached a strategic cooperation to jointly promote the research and commercialization of NK cell therapy

300255

601089

688658

688221

Innovative drug concept stocks rose at the beginning of trading, with YKYY up over 10%, Froniter Biotechnologies up over 9%, and CSBIO, Porton, and Foyou Pharma leading in gains

CSBIO

Foyou Pharma

YKYY

Froniter Biotechnologies

Innovative drug concept stocks rose at the beginning of the trading session, YKYY increased by over 10%

Porton announced that the company plans to cancel all 2.0223 million shares repurchased in 2022, accounting for 0.37% of the company's total share capital. This plan has been approved by the board of directors and the supervisory board, and is subject to approval by the shareholders' meeting. The shares repurchased by the company were intended for implementing equity incentives or employee stock ownership plans, but due to the expiration of the retention period, the purpose has been changed to cancellation and reduction of registered capital. This move will not have a substantial impact on the company's financial condition and operating results

Porton: Plans to cancel 2.0223 million shares

Porton rose nearly 10%, with Kanglong Huacheng, Kangpeng Technology, and Hitec Bio rising over 5%, followed by Zhaoyan New Drug, Tigermed, Meinuohua, and Medisyn

CRO concept stocks remain active, Porton rises nearly 10%

002821

06821

300759

03759

603259

02359

CRO concept stocks surged again, WuXi AppTec hit the daily limit, Porton reached a 20% limit up, Medicilon rose over 10%, Asymchem and Pharmaron had significant gains

Porton(300363.SZ)